Mylan Acknowledges FDA Letter, Which Will Not Impact the Commercial Status of Amnesteem

PITTSBURGH--(BUSINESS WIRE)--June 19, 2003--Mylan Laboratories' (NYSE:MYL) brand subsidiary, Bertek Pharmaceuticals received an Untitled Letter from the United States Food and Drug Administration (FDA) regarding a certain specific reference on its Amnesteem® website.

Having been made aware of the FDA's concern, Bertek took immediate action to address this matter.

The company further stated that this FDA notification does not impact the commercial status of Amnesteem.

Mylan Laboratories Inc. is a leading pharmaceutical company that develops, manufactures and markets generic and proprietary prescription products. Mylan has two operating segments that market an extensive line of generic and branded products through four business units: Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories, Inc. and Bertek Pharmaceuticals Inc. For more information about Mylan, visit www.mylan.com.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. We refer you to the risk factors and other disclosures contained in our periodic SEC filings. We undertake no duty to update our forward-looking statements, even though our situation may change in the future.

CONTACT: FOR: Mylan Laboratories Inc. Kris King, 724/514-1800

SOURCE: Mylan Laboratories